News

The panel recommended approval of the device contingent upon several conditions, including long-term follow up of current pivotal trial patients, a new post approval study of new patients

The right grants to Becton Dickinson (BD) an exclusive discussion period through March 31, 2008 during which the companies will explore a possible product development relationship and definitive

The study was a randomized, double-blind, placebo-controlled, multi-center, four-week inpatient study that enrolled 604 patients. Following fixed-dose titration, inpatients were randomized to receive iloperidone at 24mg/day, ziprasidone at

Exact Sciences has a portfolio of over 110 issued patents and over 60 pending patent applications in the US, Europe, Japan, Canada, Australia and elsewhere. Jeffrey Luber, president

Neurocrine said that it is now preparing a formal meeting request to the FDA to discuss the 2007 approvable letter. The FDA has notified the company that its

Lazard Freres & Co acted as the lead placement agent with Susquehanna Financial Group and CRT Capital Group acting as co-placement agents in the transaction. Michael Flavin, chairman

The agreement contemplates the merger of a new subsidiary of I-Flow into AcryMed, with AcryMed being the surviving corporation as a wholly owned subsidiary of I-Flow. I-Flow’s obligation

Under the terms of this agreement, Sareum will continue to apply its skills in high-throughput protein expression, purification and structure determination on drug discovery targets designated by Genentech.

PRO-513 is a patented formulation of diclofenac potassium powder for oral solution, which has been demonstrated to enhance the pharmacokinetic profile of diclofenac. This formulation is expected to